Elranatamab-bcmm is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T cell engager indicated in the United States for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).
UPCOMING EVENTS
Topic 1:
A clinical overview
Session 1
October 11th, 2023
4:00 p.m. - 4:30 p.m. MST
Session 2
October 26th, 2023
4:00 p.m. - 4:30 p.m. EST

Charlotte Wagner,
PharmD, RPh, BCOP
University of Utah Health -
Huntsman Cancer Institute (HCI) -
Hematologic Cancers Program


Mary Steinbach, DNP, APRN
University of Utah Health -
Huntsman Cancer Institute (HCI) -
Hematologic Cancers Program

Topic 2:
A guide to handling and administration
Session 1
October 24th, 2023
4:00 p.m. - 4:30 p.m. MST
Session 2
November 2nd, 2023
4:00 p.m. - 4:30 p.m. EST

Charlotte Wagner,
PharmD, RPh, BCOP
University of Utah Health -
Huntsman Cancer Institute (HCI) -
Hematologic Cancers Program


Mary Steinbach, DNP, APRN
University of Utah Health -
Huntsman Cancer Institute (HCI) -
Hematologic Cancers Program

Topic 3:
Patient management strategies
Session 1
November 14th, 2023
3:00 p.m. - 3:45 p.m. MST
Session 2
November 16th, 2023
4:00 p.m. - 4:45 p.m. EST

Charlotte Wagner,
PharmD, RPh, BCOP
University of Utah Health -
Huntsman Cancer Institute (HCI) -
Hematologic Cancers Program


Mary Steinbach, DNP, APRN
University of Utah Health -
Huntsman Cancer Institute (HCI) -
Hematologic Cancers Program

Topic 4:
A case based program
Session 1
January 30th, 2024
3:00 p.m. - 3:30 p.m. MST
Session 2
January 25th, 2024
4:00 p.m. - 4:30 p.m. EST

Charlotte Wagner,
PharmD, RPh, BCOP
University of Utah Health -
Huntsman Cancer Institute (HCI) -
Hematologic Cancers Program


Mary Steinbach, DNP, APRN
University of Utah Health -
Huntsman Cancer Institute (HCI) -
Hematologic Cancers Program
